Posts

Servier’s $1.55B sevasemten bet hits pivotal trial setback

on

CVS plans to separate its pharmacy and healthcare businesses

on

Midstream Health raises $20 million to improve hospital finances

on

What the US midterm elections could mean for biopharma

on

Pelacarsen’s trial miss clouds the future of Lp(a) cholesterol drugs

on

Bayer says it is working on a U.S. MFN pricing agreement

on

FDA grants uniQure’s Huntington’s gene therapy Priority Review

on

Pfizer beats Q3 estimates and raises 2026 outlook

on

Novartis ends BioArctic neuroscience deal worth up to $802 million

on

Midstream Health raises $20 million to improve hospital finances

on

CinRx and Graviton form CinRock to pursue ROCK2 therapies for heart and lung conditions

on

FDA partial hold on Bright Minds’ BMB-101 trial sends shares sharply lower

on

Karyopharm’s proposed Ayrmid deal is part of a Chapter 11 restructuring

on